GFAP and Alzheimer disease: Because chronic treatment with a P2Y1 receptor antagonist reduced astrocyte Ca2+ signals in AD model mice but not GFAP upregulation, astrocyte Ca2+ signals may be relevant to induction of GFAP expression rather than maintenance of the expression.